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Abstract: We characterized the effect of systemic therapy given after portal vein embolization (PVE)
and before hepatectomy on hepatic tumor and functional liver remnant (FLR) volumes. All 76 patients
who underwent right PVE from 2002–2016 were retrospectively studied. Etiologies included colorectal
cancer (n = 44), hepatocellular carcinoma (n = 17), cholangiocarcinoma (n = 10), and other metastases
(n = 5). Imaging before and after PVE was assessed. Chart review revealed systemic therapy
administration, SNaPshot genetic profiling, and comorbidities. Nine patients received systemic
therapy; 67 did not. Tumor volume increased 28% in patients who did not receive and decreased
−24% in patients who did receive systemic therapy (p = 0.026), with no difference in FLR growth
(28% vs. 34%; p = 0.645). Among 30 patients with genetic profiling, 15 were wild type and 15 had
mutations. Mutations were an independent predictor of tumor growth (p = 0.049), but did not impact
FLR growth (32% vs. 28%; p = 0.93). Neither cirrhosis, hepatic steatosis, nor diabetes impacted
changes in tumor or FLR volume (p > 0.20). Systemic therapy administered after PVE before hepatic
lobectomy had no effect on FLR growth; however, it was associated with decreasing tumor volumes.
Continuing systemic therapy until hepatectomy may be warranted, particularly in patients with
genetic mutations.
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1. Introduction
Portal vein embolization (PVE) is performed before hepatic lobectomy for primary and secondary
liver malignancy to increase the size of the functional liver remnant (FLR) to avoid post-hepatectomy
failure [1,2]. During the interval between PVE and surgery, tumor growth may occur, and can be
mediated by several pathways. For instance, the RAS proteins, which are GTPases involved in cell
signaling, are among the most common oncogenes, with KRAS mutations determining the response to
certain systemic therapies [3]. PI3Ks, intracellular signal transducer enzymes, stimulate RAS pathways
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while inhibiting tumor suppressor pathways including the tumor protein p53 [4,5]. PVE may induce
tumor growth by a variety of mechanisms, such as altered arterial supply to the liver or stimulating
growth factor and cytokine pathways [6,7].
Because of the potential of tumor growth after PVE while patients await surgery, some propose
administering systemic therapy during this interval [8]. However, systemic therapy may prevent
hyperplasia and the growth of the FLR, reducing PVE efficacy. PVE is expected to increase the FLR
volume by 25%–50%, with non-cirrhotic livers demonstrating a larger increase in volume compared
with cirrhotic livers [9]. Several studies have not shown a significant impact on FLR hypertrophy by
the administration of chemotherapy [9,10]. However, one study reported that FLR growth was reduced
by a third by pre-surgical chemotherapy in the setting of colorectal metastasis [11], and other studies
have shown a trend for reduced FLR hypertrophy in patients on chemotherapy after PVE [12,13].
The purpose of this study was to characterize the effect of PVE and cancer-related genetic
mutations on tumor and liver volume changes in patients who were or were not treated with systemic
therapy during the interval prior to surgical lobectomy.
2. Materials and Methods
In this retrospective, single institution, Health Insurance Portability and Accountability
Act-compliant, Institutional Review Board-approved study, the requirement for informed consent was
waived. All consecutive patients who underwent right PVE from January 2002 to December 2014 were
identified using the radiology department PACS search engine.
A total of 76 patients (30F, 46M) with a mean age of 61 years (range 37–83) who underwent
right PVE for right liver malignancy were included (Table 1). Patients who received chemotherapy
were significantly younger (p < 0.001), and none had primary hepatic malignancy. Overall, etiologies
included colorectal cancer (n = 44), hepatocellular carcinoma (HCC; n = 17), cholangiocarcinoma
(n = 10), gastrointestinal stromal tumor (3), thyroid cancer (1), and lacrimal gland tumor (1).
Table 1. Demographics and pre-procedural characteristics of patients who did and not receive
chemotherapy between portal vein embolization (PVE) and hepatic lobectomy.
Study Population No Chemotherapy Chemotherapy p Value
Number of patients 67 9
% Male 61% 56% 0.745
Age 63 ± 1 year 50 ± 3 year <0.001
Pre-PVE FLR 35 ± 1% 35 ± 3% 0.960
Tumor volume 115 ± 31 cc 105 ± 50 cc 0.910




Colorectal cancer 54% 89%
Other metastasis 6% 11%
Pre-procedure magnetic resonance imaging (MRI) or computed tomograhy (CT) was performed
33 ± 5 days before PVE, whereas post-procedure MRI or CT was performed 33 ± 6 days after PVE.
All PVEs involved the right portal vein prior to planned right hepatectomy. PVE was performed in
standard fashion using a right lobe approach with both particles and metallic coils [14] (Figure 1).
Images were assessed with TeraRecon (Foster City, CA, USA) by a radiologist blind to the patient’s
treatments to calculate liver and tumor volumes before and after PVE.
Chart review revealed systemic therapy administration, genetic profiling, and comorbidities
including diabetes, cirrhosis, and hepatic steatosis. Genetic profiling with SNaPshot (Thermo Fisher
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Scientific, Springfield Township, NJ, USA), a high-throughput PCR assay that detects over 100 gene
mutations [15], was performed in 30 patients in the cohort.J. Clin. Med. 2017, 6, 26  3 of 7 
 
Figure  1.  (A)  Pre‐procedure  CT  imaging  demonstrates  a  right  hepatic  metastasis  (arrow)  from 
colorectal cancer, with a diminutive left lobe; (B) Tranhepatic portography (arrow) is obtained after 
portal access is achieved via the right portal vein; (C) The right portal branches have been embolized 
with  particles  and  metallic  coils  (arrow);  (D)  200×  magnification  H&E  stain  slide  demonstrates 











Figure 1. (A) Pre-procedure CT imaging demonstrates a right hepatic metastasis (arrow) from colorectal
cancer, with a diminutive left lobe; (B) Tranhepatic portography (arrow) is obtained after portal access
is achieved via the right portal vein; (C) The right portal branches have been embolized with particles
and metallic coils (arrow); (D) 200× magnification H&E stain slide demonstrates Embosphere particles
within a portal vein (arrow); (E) Gross specimen after right hepatectomy demonstrates particles within
the embolized right hepatic lobe. White bar indicates 5 cm.
Statistical analysis was performed with GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA,
USA), with p < 0.05 used for statistical significance. Data are presented as mean ± standard error.
Tumor growth was calculated by subtracting the volume of the hepatic tumor(s) after PVE from
the volume of the tumor before PVE, then dividing by the volume before PVE, and presented as a
percentage. FLR growth was similarly calculated using the volume of the left lobe before and after
PVE. Because data were not normally distributed, by Shapiro-Wilk test, Mann-Whitney U test was
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used to compare means. Chi-square tests were used to compare categorical data. Multiple regressions
were used to assess the impact of multiple variables on tumor and FLR growth.
3. Results
Of the 76 patients, nine patients received systemic therapy and 67 did not (Table 2). Patients who
did not receive systemic therapy had increased tumor volume (28% ± 13%) whereas patients who
received systemic therapy had decreased tumor volume (−24% ± 23%) (p = 0.026). However, there
was no significant difference in the increase in FLR between patients who received systemic therapy
(28% ± 8%) compared to those who did not (34% ± 4%) (p = 0.645).
Table 2. Systemic therapy administered to patients after PVE before surgical lobectomy.
Age Gender Etiology Chemotherapy Regimen
66 Male Colorectal cancer FOLFOX/bevacizumab
44 Female Colorectal cancer 5FU
39 Female Colorectal cancer FOLFIRINOX
55 Female Colorectal cancer FOLFOX
40 Male Colorectal cancer FOLFOX/bevacizumab, FOLFIRI/cetuximab
50 Male Colorectal cancer FOLFOX
61 Female Colorectal cancer FOLFOX
51 Male Colorectal cancer FOLFIRI, bevacizumab, 5-FU
40 Male GIST Sunitinib
Because none of the patients who received systemic therapy had primary liver malignancy
(cholangiocarcinoma or HCC), a subgroup analysis was performed comparing patients with metastatic
liver tumors who did and did not receive systemic therapy. Patients with metastatic disease who did
not receive systemic therapy had a 46% ± 20% increase in tumor volume; in contrast, patients with
metastatic disease who did receive systemic therapy had a 24% ± 23% reduction in tumor volume
(p = 0.013). In contrast, for patients with metastatic disease, there was no significant difference in FLR
growth among those who did not (38% ± 5%) and did (28% ± 8%) receive systemic therapy.
Multiple regression analysis was used to assess the impact of the presence of cirrhosis, hepatic
steatosis, and diabetes on changes in the FLR volume. The model was not significant (p = 0.538) and
none of the variables were independent predictors of FLR growth (p > 0.20). Similarly, tumor growth
was also not predicted by a model assessing cirrhosis, steatosis, and diabetes (p > 0.40), with no variable
independently predictive (p > 0.10).
Of the 76 patients, 61 (80%) underwent hepatectomy as planned, on average 45 ± 3 days after
PVE (Table 3). Seven patients had progression of disease precluding hepatectomy, four of which
were noted intraoperatively, and three on post-PVE imaging. Of note, all seven of the patients with
progression of disease precluding surgery did not receive chemotherapy after PVE before planned
resection. Six patients had insufficient hypertrophy of the FLR precluding hepatectomy; four of
these were noted on post-PVE imaging and two were noted intraoperatively. Of the six patients with
insufficient hypertrophy, one received chemotherapy and the others did not. Of the two intraoperative
cases with insufficient FLR hypertrophy, one had a partial resection as part of a new planned staged
resection, and the other had a portal vein ligation. The final two patients did not undergo hepatectomy
due to complications from PVE: one patient had a liver abscess because thermal ablation was also
performed at the time of PVE, and the other patient had hemorrhagic shock during PVE due to an
arterioportal shunt that was treated with arterial embolization. Both of these patients were too ill to
undergo additional surgery.
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Table 3. Outcomes after PVE.
Volume Changes after PVE No Chemotherapy Chemotherapy p Value
% Change in tumor volume 28% ± 13% −24 ± 23% 0.026
% Daily change in tumor volume 0.5% ± 0.2% −0.3% ± 0.3% 0.092
% Change in FLR volume 34% ± 4% 28% ± 8% 0.740
% Daily change in FLR volume 0.7% ± 0.1% 0.4% ± 0.1% 0.287
% Cases that underwent hepatectomy 79% 88% 0.489
Among the 30 patients with genetic profiling with SNaPshot, 15 were wild type and 15 had one
or more mutations including KRAS (eight), TP53 (five), KIT (one), PI3K (one), MSH2 (one), and SDHC
(one). Three patients with mutations and three patients with the wild type genotype received
chemotherapy. Patients with mutations had greater increased tumor volume (77% ± 46%) compared
to those without (10% ± 20%), though this difference was not significant by the Mann-Whitney U test
(p = 0.412). Patients with mutations had similar FLR growth (32% ± 8%) compared to patients without
mutations (28% ± 8%) (p = 0.806). Multiple regression was performed with diabetes, hepatic steatosis,
administration of systemic therapy, and genetic mutation as input variables and tumor growth as
the output. Though the model was not significant (p = 0.097), the presence of genetic mutations was
the only significant independent predictor of increased tumor growth after PVE (p = 0.049). Among
the 15 patients with mutations, 12 underwent surgical resection as planned, one did not due to
progressive disease and two did not due to insufficient hypertrophy. Among the 15 wild-type patients,
11 underwent surgery as planned, two did not due to progressive disease, and two did not due to
insufficient hypertrophy.
4. Discussion
Chemotherapy given after PVE and before hepatic lobectomy had no effect on FLR
growth. However, patients who did not receive chemotherapy had significant increases in tumor
volume, whereas those who continued chemotherapy had decreased tumor volume. Theoretically,
chemotherapy could impact FLR growth by a number of mechanisms. Embolization stimulates
hepatocyte growth via a number of mechanisms, including stimulation of proinflammatory cytokines
and growth factors that are directly or indirectly suppressed by systemic immunotherapies and
chemotherapies [16]. Indeed, FLR growth was reduced by a third when chemotherapy was given to
patients undergoing PVE for colorectal metastasis [11]. In the present study, there was a slight decrease
in FLR growth in patients on chemotherapy compared with those not on chemotherapy (28% vs. 34%);
however, as in other prior studies, this trend did not reach significance [12,13].
Several prior studies have suggested that PVE could induce tumor growth by a variety of
mechanisms, such as growth factor and cytokine pathway alterations or changes in the arterial
supply to the liver [6,7]. Furthermore, embolization activates pre-inflammatory cytokine pathways
and mediators, including interleukin-6 and tumor necrosis factor-alpha, which then could trigger
growth of tumors both within the liver and at distant sites [16,17]. Thus, several papers have
described the progression of disease while chemotherapy is withheld for PVE and surgery [6–8,10].
However, it is also possible that existing tumors are not specifically triggered to grow, but rather are
merely no longer inhibited because the chemotherapy is withheld. In our study, we observed that
withholding chemotherapy was associated with tumor growth, whereas administering chemotherapy
was associated with tumor volume reduction.
A subset of patients underwent genetic profiling with SNaPshot analysis. The mean tumor growth
was 77% among patients with genetic mutations, compared with only 6% for wild-type patients.
The two most commonly detected genetic mutations in this study were KRAS and TP53. Mutations
in KRAS, a gene encoding a component of the epidermal growth factor receptor signaling network,
confer resistance to certain systemic therapies including cetuximab [18], and are associated with
significantly reduced survival [19]. Mutations in TP53, a gene encoding a tumor suppressor protein [20],
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are associated with increased recurrence and decreased survival in colorectal cancer [21]. A previous
study demonstrated that KRAS and TP53 mutations were associated with reduced survival after
radioembolization, an effect possibly mediated by angiogenic derangements including intratumoral
vascular shunting [22], which could impair the delivery of therapeutic agents [23]. Because patients
with genetic mutations have more rapid tumor growth and metastasis, withholding targeted systemic
therapies may put such patients at greater risk for progression of disease while awaiting surgery.
The primary study limitations are its retrospective nature and the relatively low sample size.
Only a fraction of patients received chemotherapy and underwent genetic profiling. There may
be undetected bias that influenced which of the patients received systemic therapy or underwent
SNaPshot testing. The variation in genetic mutations between patients, and in the type of
chemotherapies delivered to each patient, precludes assessing the impact of specific genes and
chemotherapies. Also, no patient with primary liver malignancy received chemotherapy, so it is
not possible to characterize the potential effect of systemic treatment on FLR and tumor growth for
these patients. The smaller sample size for patients receiving chemotherapy may have limited our
ability to detect a significant difference between chemotherapy and no chemotherapy groups regarding
changes in FLR. Power analysis reveals that 490 patients would be necessary to detect such a difference
with 80% power. Additionally, future studies could assess measures of liver function before and after
resection, and post-operative complications and survival, to assess the impact of pre-surgical systemic
therapy on functional outcomes beyond the impact on hepatic and tumor volumes.
5. Conclusions
In summary, administration of systemic chemotherapy after PVE before hepatic lobectomy did
not have a significant impact on FLR growth, but did lead to reduced tumor progression or even
tumor shrinkage. Given these findings, chemotherapy appears to be safe and effective and should
likely not be withheld, particularly in patients with genetic mutations that may be prone to more rapid
tumor progression.
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